Senores Pharmaceuticals Reports Zero Deviation in Preferential Issue Fund Utilization
Senores Pharmaceuticals Ltd · Others (Uncategorized) · 29 Oct 2026, 11:01 pm
Senores Pharmaceuticals Reports Zero Deviation in Preferential Issue Fund Utilization Senores Pharmaceuticals confirmed nil deviation in the utilization of proceeds from its preferential issue of 11.70 lakh convertible equity warrants raised on 28th Mar'26 at ₹812 per warrant, totaling ₹95.00 crore. As of 30th Sep'26, the company deployed ₹16.91 crore, including ₹6.84 crore toward working capital, ₹6.15 crore as loans to subsidiaries for working capital, and ₹3.92 crore for general corporate purposes. Product development expenditure allocation of ₹25.00 crore remains unutilized. The statement was reviewed by the Audit Committee and approved on 29th Oct'26.
Original exchange filing (PDF)
More announcements from Senores Pharmaceuticals Ltd
- We are pleased to announce that the manufacturing facility of our Subsidiary Company., Ratnatris Pharmaceuticals Private Limited has been awarded with the prestigious PIC/S GMP certification .... · 18 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding transcript of earnings conference call held on October 29, 2026 · 05 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026 · 30 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended on September 30, 2026 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 2026 · 29 Oct 2026
- We enclose herewith the Investor Presentation for Q2 & H1FY27 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of joint Statutory Auditor of the Company · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding media release · 29 Oct 2026
